Table 1

Patient demographics and baseline characteristics

Placebo10 mg empagliflozin25 mg empagliflozinTotal
n271276276823
Male sex, n (%)168 (62.0)171 (62.0)156 (56.5)495 (60.1)
Age, years60.3 (8.8)60.6 (8.5)59.9 (9.7)60.2 (9.0)
Race, n (%)
 White256 (94.5)258 (93.5)257 (93.1)771 (93.7)
 Black/African American13 (4.8)14 (5.1)14 (5.1)41 (5.0)
 Asian1 (0.4)3 (1.1)4 (1.4)8 (1.0)
 Other1 (0.4)1 (0.4)1 (0.4)3 (0.4)
BMI, kg/m232.4 (4.9)32.4 (5.3)33.0 (5.0)32.6 (5.1)
eGFR, mL/min/1.73 m2 (MDRD)85.0 (17.0)83.4 (16.7)83.5 (17.8)84.0 (17.2)
HbA1c, % [mmol/mol]7.90 (0.72) [63 (7.9)]7.87 (0.77) [63 (8.4)]7.92 (0.72) [63 (7.9)]7.90 (0.74) [63 (8.1)]
FPG, mmol/L8.9 (2.0)8.7 (2.1)9.0 (2.1)8.9 (2.1)
Years since diagnosis of type 2 diabetes, n (%)
 ≤17 (2.6)9 (3.3)12 (4.3)28 (3.4)
 >1 to 570 (25.8)62 (22.5)73 (26.4)205 (24.9)
 >5 to 1083 (30.6)92 (33.3)90 (32.6)265 (32.2)
 >10111 (41.0)113 (40.9)101 (36.6)325 (39.5)
SBP (office measurement), mmHg142.0 (12.4)142.3 (12.1)141.9 (12.5)142.1 (12.3)
SBP (mean over 24 h), mmHg131.7 (11.8)131.3 (13.0)131.2 (12.1)131.4 (12.3)
DBP (office measurement), mmHg83.7 (7.1)84.1 (7.3)83.8 (6.8)83.9 (7.0)
DBP (mean over 24 h), mmHg75.2 (7.5)75.1 (8.3)74.6 (7.5)75.0 (7.8)
Pulse rate (mean 24 h), bpm*77.62 (9.93)75.48 (10.05)76.10 (10.33)
Number of antihypertensive medications, n (%)
 022 (8.1)19 (6.9)21 (7.6)62 (7.5)
 1115 (42.4)122 (44.2)116 (42.0)353 (42.9)
 2132 (48.7)120 (43.5)132 (47.8)384 (46.7)
 >22 (0.7)15 (5.4)7 (2.5)24 (2.9)
  • Data are mean (SD) from the FAS unless otherwise indicated.

  • * Treated set.